Author: admin
Updated: FDA Declines Pfizer’s ‘Herceptin-Equivalent’ Biosimilar Approval, Needs More Info
USFDA declined the approval of Pfizer’s Herceptin biosimilar for breast cancer treatment. Pfizer’s biosimilar-PF-05280014 has shown equivalence in the objective response rate with Herceptin in HER2-positive metastatic breast cancer patients in clinical studies.
Roche’s Blockbuster Drug Rituxan Prepares for New Rare Disease Treatment
Roche’s top-selling rheumatoid arthritis drug, Rituxan® (rituximab) received US FDA Priority Review status for the treatment of pemphigus vulgaris (PV), ...
HealthifyMe Raises $12 M in Series B Round
HealthifyMe New Funding Bangalore-based digital health and fitness startup, HealthifyMe has raised $12 million in a Series B funding round ...